Qiagen stock gets a fresh FDA catalyst from QIAstat-Dx

Published on 09/28/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock carries a USD 44.18 NYSE reference after Q2 revenue reached USD 535.04 million. A new FDA clearance expands QIAstat-Dx to 33 targets.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) was last at USD 44.18 on the NYSE on September 25, 2026, down 0.85 percent from the prior session. The latest catalyst is a U.S. FDA clearance that completes the companys QIAstat-Dx bloodstream infection portfolio, as StockTitan reported on September 28, 2026.

FDA clearance expands the menu

The newly cleared QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial targets and 18 antimicrobial resistance markers. Together with the previously cleared companion panel, the portfolio covers 33 pathogen targets and 28 resistance markers, with results delivered in one hour, according to StockTitan.

The system is available in more than 100 countries and had more than 5,200 cumulative placements at the end of 2025. That installed base gives the clearance an operational angle: the new panel extends an existing workflow rather than introducing a standalone instrument.

Q2 revenue beats consensus

Qiagen reported USD 535.04 million in Q2 2026 revenue against consensus of USD 527.50 million, while earnings per share reached USD 0.62 versus USD 0.60 expected, MarketBeat reported on September 26, 2026. The revenue beat was USD 7.54 million, or 1.43 percent, while the EPS beat was USD 0.02.

The valuation backdrop remains mixed. MarketScreener reported on September 9, 2026, that UBS cut its price target from USD 52.00 to USD 47.00 while retaining a Neutral rating. The target is USD 2.82 above the reference price, equal to 6.38 percent above USD 44.18.

Stock remains below its yearly high

Qiagen stock traded between USD 43.99 and USD 44.80 during the September 25 session. Its 52-week range was USD 32.53 to USD 57.82, placing the reference price 23.59 percent below the high and 35.81 percent above the low.

Qiagen has also scheduled an extraordinary general meeting for November 6, 2026, at 2:00 p.m. CET to vote on Jonathan Pratt joining the managing board, according to Business Wire on September 18, 2026.